This systematic review was limited by literature that was lacking in survival analyses and inconsistent definitions of drug discontinuation across the literature.

Hidradenitis suppurativa has a significant negative impact on patient quality of life, which has been reported to be greater than that of atopic eczema and psoriasis.

After 16 weeks of treatment with dupilumab, the median SCORAD score decreased 55%.

Patients with psoriasis, particularly those with risk factors and severe disease, should receive appropriate screening and preventative intervention.

Compared with foam vehicle, calcipotriol plus betamethasone dipropionate foam offers more rapid and effective itch relief, with associated significant improvements in sleep and Dermatology Life Quality Index scores.

Baricitinib, a Janus kinase inhibitor, is currently approved under the brand name Olumiant for the treatment of moderately-to-severely active rheumatoid arthritis.

Overall therapeutic response was statistically higher for patients in the combination therapy group vs either single agent group.

Investigators observed differences and similarities in molecular and histopathologic profiles in skin lesions of patients with psoriasis treated with risankizumab vs ustekinumab.

Jeuveau, an aesthetic-only neurotoxin, was evaluated in 2 US Phase 3 placebo-controlled trials and a European and Canadian Phase 3 head-to-head trial vs onabotulinumtoxinA (Botox Cosmetic; Allergan).

194 participants with mild to moderate atopic dermatitis were randomly assigned to receive vehicle cream or 0.1%, 0.3%, or 1.0% PAC‐14028 cream twice daily.